Abstract
Cannabigerol (CBG), a phytocannabinoid with anti-inflammatory and antioxidant properties, has been explored as a potential therapeutic agent in various neuropsychiatric conditions, including Autism Spectrum Disorder (ASD). However, its low water solubility and rapid metabolism limit its bioavailability and therapeutic efficacy. The encapsulation of CBG aims to overcome pharmacokinetic cha…